China

George Clinical’s largest hub outside the head office of Sydney, offering full CRO services and a site network that spans the country.

George Clinical in China

Tweet about this on TwitterShare on FacebookShare on LinkedIn

China is George Clinical’s largest hub outside the head office of Sydney, offering full CRO services and a site network that spans the country.

With its immense potential for patient recruitment and a rapidly growing pharmaceutical market, China, currently the third largest in the world, is an obvious choice for many when entering the Asian market.

The Chinese healthcare delivery system consists of public hospitals and community healthcare centers, with an increasing private care system. Only GCP accredited sites are eligible for running commercial Phase I, II and III studies, and this accreditation can only be achieved by public hospitals in China. The accreditation is issued by the CFDA and NHPFC based upon a site inspection. Accreditation is renewed every 3 years, with a quality review performed by the PFDA every year.

George Clinical has an extensive network of over 260 trial centers in 50 cities for Phase II-IV trials, and a wider network that includes community health centers in semi-urban and rural areas for Phase IV trials.

What are the benefits of conducting clinical trials in China?

  • China has access to a large patient pool
  • Rapidly developing medical infrastructure in urban centres and centres of excellence for many common diseases such as hypertension, diabetes and renal disease
  • Low operational costs

What are the prevalent diseases in China?

  1. Stroke
  2. Ischaemic Heart Disease
  3. Chronic obstructive pulmonary disease
  4. Cancer
  5. Road injury
  6. Hypertension
  7. Diabetes mellitus
  8. Lower respiratory infections

George Clinical China News

“中英减盐行动”项目在京正式启动

2017年10月11日, “中英减盐行动”项目启动仪式在北京召开。中华预防医学会会长王陇德院士、国家卫生计生委宣传司司长毛群安、中国高血压联盟主席吴兆苏教授、英国伦敦玛丽女王大学的Graham MacGregor教授及何凤俊博士、乔治健康研究所所长Craig Anderson教授、副所长张普洪教授、英国驻华大使馆一等秘书Ash Kirchner、世界卫生组织驻华代表处疾病控制组协调员Fabio Scano、中国健康教育中心李长宁主任、中国疾病预防控制中心李新华书记、国家食品安全风险评估中心严卫星副主任,以及部分省疾病预防控制中心领导和专...

Action on Salt China launched in Beijing

On 11th October, 2017, the Launch event of ASC Programme – NIHR Global Health Research Unit Action on Salt China – was successfully held in Beijing.

急性脑出血包括强化降压的组合性管理研究(INTERACT 3)正式启动

2017年10月,INTERACT3研究——INTERACT系列研究第三篇章——“急性脑出血包括强化降压的组合性管理研究”正式启动, 研究覆盖全国80+家医院,急性脑出血的强化降压治疗研究再次扬帆起航。

INTERACT3 study officially launched

In October 2017, INTERACT3, the third in a series of INTERACT studies, has been launched. This time called the INTEnsive care bundle with blood pressure reduction in Acute Cerebral haemorrhage Trial, it was successfully launched across a network of more than 80 hospitals...

Workshop on Media Doctor Toolkit and Critical Appraisal Skills Program at Peking University

The workshop on Media Doctor Toolkit and Critical Appraisal Skills Program was conducted at the School of Journalism and Communication, Peking University on 23rd June.

PLOS ONE: 基于学校的儿童及其家庭减盐干预极具成本效益

2017年9月13日,国际知名综合性学术期刊PLOS ONE在线发表了北京大学医学部乔治健康研究所减盐项目的最新研究成果–中国基于学校的儿童及其家庭减盐干预的成本及其成本效益(Cost and cost-effectiveness of a school-based education program to reduce salt intake in children and their families in China)。

Contact

George Clinical Address:
Level 18, Tower B, Horizon Tower
Haidian District
Beijing, 100088
P.R. China

2223, 22/F Tomson Commercial Building,
710 Dongfang Road, Pudong District
Shanghai, 200122
P.R. China

Details

Number of Personnel: 50
In-country Services:

Beijing
Project Management, Clinical Operations, Data Management, Medical and Safety Services, Clinical Compliance, Regulatory Services, Statistics, Health Economics

Shanghai
Clinical Operations

Chengdu
Clinical Operations

Harbin
Project Management, Clinical Operations

Population: 1.4 billion
Official Language: Putonghua (Mandarin). Local dialects may be used
Hospital Records Language: Simplified Chinese
Electronic Hospital Records: Currently, paper records are used.

Twitter Facebook LinkedIn